Regeneron Pharmaceuticals, Inc. Securities Class Action

Class Period

August 1, 2025 - May 15, 2026

Motion Deadline

September 14, 2026|55 days left

Please submit the form below if you believe you have incurred losses.

First Name *

Last Name *

Email Address *

Phone Number*

Address Line 1

City

State / Province / Region

Postal Code

Country

Investment Details

Estimated Losses *

Do you still retain shares?

Transactions Information

Select a file or drag and drop here

PDF, XLS, or CSV, file size no more than 25MB

Additional information

By clicking the submit button above, I acknowledge that this form is not intended to and does not establish an attorney-client relationship between myself and Pomerantz LLP ("Pomerantz" or "The Firm"), and that the submission or receipt of information to the Firm or one of its attorneys via this form, website, e-mail or telephone does not create an attorney-client relationship. Prior results do not guarantee a similar outcome in future cases.

Pomerantz LLP does not share your information with others. There is no cost or obligation for you to submit. By submitting this form, you are authorizing us to contact you regarding this case and/or future cases.

Allegations

On April 29, 2026, during during Regeneron’s first quarter earnings call, the Company disclosed that the Phase III Fianlimab-Libtayo Study had been altered, expanding the number of patients in the study eligible for “analysis of progression-free survival.” On this news, Regeneron’s stock price fell $45.41 per share, or 6.21%, to close at $686.36 per share on April 29, 2026. Then, on May 15, 2026, Regeneron issued a press release disclosing that the “Phase 3 Trial of Fianlimab . . . did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS).” On this news, Regeneron’s stock price fell $68.57 per share, or 9.82%, to close at $629.68 per share on May 16, 2026.

Lead Plaintiff

If you have qualifying losses, you may be eligible to serve as Lead Plaintiff. Acting as a representative for all class members seeking recovery in the lawsuit, the Lead Plaintiff plays an important role in the litigation, including selecting a law firm to serve as Lead Counsel and approving the final settlement. There is no cost whatsoever to seek or participate as a Lead Plaintiff. The Lead Plaintiff may also receive a monetary award for their participation in the suit.

About the Firm

Founded in 1936, Pomerantz LLP is the oldest law firm in the world dedicated to championing investor rights. Throughout its history, the Firm has won landmark decisions that have initiated historic corporate governance reforms and shaped the law to better protect shareholders. Pomerantz has successfully resolved hundreds of securities class actions as Lead Counsel, recovering billions of dollars on behalf of defrauded investors with many settlements breaking previously held records. Pomerantz is headquartered in New York City, with offices in Los Angeles, Chicago, Paris, London, and Tel Aviv.